Literature DB >> 27621996

PCR Results and PMTCT Treatment Outcomes among HIV-Exposed Infants in a Tertiary Hospital in Nigeria, 2010-2014.

Isaac Oludare Oluwayemi1, Simeon Oladele Olatunya1, Ezra Olatunde Ogundare1.   

Abstract

BACKGROUND: Early infant diagnosis (EID) of human immunodeficiency virus (HIV) infection in pediatrics with the use of DNA polymerase chain reaction (PCR) is a way of assessing the retroviral status of HIV-exposed infant with the view of early commencement of treatment for infected infants. It also serves as a way of assessing the effectiveness of prevention of mother-to-child transmission of HIV (PMTCT) in health care facilities.
METHODS: This was a 5-year prospective cross-sectional study at the Ekiti State University Teaching Hospital, (EkSUTH) Ado-Ekiti, Nigeria. Babies delivered to HIV-positive mothers who presented at EkSUTH between January 2010 and December 2014 were enrolled in the present study. PCR was done twice for all HIV-exposed infants. Statistical analysis was done using SPSS version 16.0.
RESULTS: One hundred and fifty eight infants were HIV exposed; 72 males and 86 females (M:F= 0.84:1). Eighty eight (55.7%) of the mothers had commenced highly active anti-retroviral therapy (HAART) before pregnancy, 56 (35.4%) during pregnancy, and 14 (8.9%) after delivery. Ten (6.3%) babies tested positive. Four (28.6%) of 14 exposed babies whose mothers commenced HAART after delivery tested positive to HIV compared to 3 (5.4%) of 56 babies whose mother commenced HAART during pregnancy and 3 (3.4%) of 88 babies whose mother commenced HAART before pregnancy. The difference was statistically significant (c(2) = 13.28, df = 4, p = 0.01). CONCLUSIONS AND GLOBAL HEALTH IMPLICATIONS: There is significant reduction in transmission of HIV from mothers to children with commencement of antiretroviral drugs before pregnancy in mothers and use of Nevirapine for all exposed babies for the first 6 weeks of life. Infants of HIV positive mothers can live healthy life free of HIV infection if their mothers participate in PMTCT program.

Entities:  

Keywords:  HIV; Infants; Nigeria; PCR; PMTCT; Treatment Outcomes

Year:  2015        PMID: 27621996      PMCID: PMC5005991     

Source DB:  PubMed          Journal:  Int J MCH AIDS        ISSN: 2161-864X


Introduction

HIV/AIDS is still a disease of public health importance and mother to child transmission (MTCT) is one of the major routes of spread of the virus.[1] About 330,000 children under the age of 15 became infected with HIV in the year 2012 worldwide according to recent estimates by the Joint United Nations Program (UNAIDS) on HIV/AIDS with more than 90 percent of paediatric HIV infections occurring in sub-Saharan African countries.[1] Most of these infections occurred during pregnancy, delivery or breastfeeding thereby making the prevention of mother to child transmission (PMTCT) a major public health approach of reducing the scourge.[2] Efforts have been made over the past few years to improve PMTCT in some sub-Sahara African countries.[3-5] One of the major ways of reducing the scourge of HIV/AIDS is by ensuring early infant diagnosis (EID). The World Health Organization (WHO) recommends that infants of HIV positive mothers should have polymerase chain reaction (PCR) done between 4 to 6 weeks of life for early infant diagnosis and commencement of antiretroviral therapy in HIV positive infants below 24 months of age.[1-3] Nigeria has about 3 million people living with HIV and the prevalence of HIV infection among pregnant women attending antenatal clinic (ANC) is about 4.4% with mother-to-child transmission of HIV occurring in about 10% of these.[4,6] Despite sustained effort at preventing mother to child transmission of HIV, infant of HIV positive mothers are still at risk of becoming infected, especially in developing countries where resources for patients’ care are limited.[7-9] In the year 2010, new pediatric HIV infection was estimated at 390,000 globally and only 23% of HIV infected children have access to antiretroviral drugs.[8,10] Data from previous studies show that only 10-12% of HIV-exposed infants have access to EID.[7,8,10,11] EID reported in this study commenced in the Pediatrics department of EkSUTH in 2009, though the samples were analyzed at Obafemi Awolowo University Teaching Hospital, (OAUTH) Osun State, Nigeria. The purpose of this study was to assess HIV reactivity rate among HIV- exposed infants seen in the Pediatrics department of EkSUTH over a five year period.

Methodology

This was a prospective cross sectional study carried out at the Pediatric ART clinic of EkSUTH, Ado-Ekiti from January 2010 to December 2014. Dried blood spot (DBS) samples, taken at six weeks of life and two weeks after discontinuation of breastfeeding at one year of life, from infants of HIV positive mothers who were delivered within and outside EkSUTH were transported by courier to OAUTH, Ile-Ife, Osun State, Nigeria (about 2 hours drive from Ado-Ekiti) for analysis. EkSUTH is a relatively new teaching hospital (upgraded from a specialist hospital to a teaching hospital in the year 2008). EID commenced in the center in 2009 and since then DBS samples for DNA PCR collected in EkSUTH were analyzed in OAUTH, Osun State, Nigeria which is the regional head area for PCR analysis for Institute of Human Virology, Nigeria (IHVN).[9,12] IHVN provides support for training of health workers in treatment of HIV patients in Nigeria.[12] Results usually become available in about two months from the time of sample collection. The PCR analysis was carried out using the GeneAmp PCR System 9700 (Perkin-Elmer, Norwalk, Conn, USA). PCR analysis of HIV-exposed infants was an ethically built-in program into the approved PMTCT services in EkSUTH. Statistical analysis was done with SPSS version 16 for Windows (SPSS Inc, Chicago, USA) after data was manually sorted and entered. The DNA PCR result of the HIV-exposed infants was categorized into positive and negative. This was cross-tabulated with the time mothers commenced HAART in pregnancy, feeding method, and the time babies commenced Nevirapine after delivery. Differences in proportion were tested with chi square and p value less than 0.05 was regarded as significant.

Results

One hundred and fifty eight HIV-exposed infants did DNA PCR test during the study period and this comprised of 72 males and 86 females giving a male to female ratio of 0.84:1 (Table I). One hundred and twenty four (78.5%) babies were delivered in government hospitals, 23 (14.6%) in private hospitals, 7 (4.4%) in faith-based homes and the remaining 4 (2.5%) at home (Table I). Delivery was by Caesarean section in 14 (8.9%) and per vaginal in 144 (91.1%). HIV status of the babies’ fathers was positive in 4 (2.5%), negative in 63 (39.9%), and unknown in 91 (57.6%). One hundred and forty two (89.9%) babies had exclusive breast feeding, 13 (8.2%) had breast milk substitute and 3 (1.9%) had mixed feeding. Eighty-eight (55.7%) mothers commenced HAART before pregnancy, 56 (35.4%) during pregnancy, and 14 (8.9%) after delivery (Table I). Nevirapine was given for the first 6 weeks of life in 147 (93.0%) of the babies while the remaining 11 (7.0%) did not receive Nevirapine. Six (54.5%) of the 11 exposed babies who did not receive Nevirapine tested positive to HIV compared to four (2.7%) of the 147 exposed babies who received Nevirapine for the first 6 weeks week of life. The difference is statistically significant (χ2 = 47.089, df =1, p = <0.001). There was no significant difference with regards to HIV positivity vis-à-vis mode of delivery as nine (90%) of the ten babies who tested positive were delivered by spontaneous vaginal delivery and this represents 6.25% (9/144) of those who were delivered per vaginal compared to one case (10%) who had caesarean section representing 7.1% (1/14) of those delivered by this method. One hundred and forty eight (93.7%) of the babies tested negative to HIV and were discharged from ART clinic after the second PCR at one year of age, while the remaining 10 (6.3%) tested positive and were enrolled for antiretroviral therapy. One (10%) of the ten babies with positive PCR result was delivered in private hospital, two (20%) at home, and the remaining 7 (70%) in government hospitals. Majority (60%) of the 10 positive infants did not receive Nevirapine in the first 6 weeks of life while the remaining four (40%) did. Most (90%) of the positive infants were breastfed exclusively while one (10%) had breast milk substitute and none had mixed feeding. Four of them were male while six were females.
Table I

Selected Characteristics of 158 Infants of HIV Positive Mothers Seen at Ekiti State University Teaching Hospital (EkSUTH), Nigeria

Characteristics of HIV- exposed Infants (N=158)FrequencyPercent
Sex

 Male7246.7

 Female8653.3

Place of delivery

 Government Hospital12478.5

 Private Hospital2314.6

 Faith based centre74.4

 Home42.5

Mode of delivery

 Vaginal14491.1

 Caesarean section148.9

Timing of mother haart commencement

 Before pregnancy8855.7

 During pregnancy5635.4

 After delivery148.9

Feeding option adopted by mother

 Exclusive breastfeeding14289.9

 Breast milk substitute138.2

 Mixed feeding31.9

Outcome

 HIV negative14893.7

 HIV positive106.3

HIV positivity outcome by feeding methods

 Exclusive breastfeeding (n=142)96.3

 Breast milk substitutes (n=13)17.7

 Mixed feeding (n=3)00.0
Selected Characteristics of 158 Infants of HIV Positive Mothers Seen at Ekiti State University Teaching Hospital (EkSUTH), Nigeria

Discussion

The prevalence of DNA PCR reactivity among HIV-exposed infants in EkSUTH, Ado-Ekiti, Nigeria was 6.3% (Table I). This is comparable to the finding of 6.5% in a similar study in Zambia[13] and 5.8% in Cape town, South Africa.[14] It is however higher than 1.8% prevalence reported by Onakpa and Tahir[10] in Sokoto, Nigeria. Reason for this difference could partly be due to the difference in duration of the study. The study from Sokoto covered a 24 month period while the present study covered a 5 year period. Also, the present study included exposed babies referred from other health facilities, while that of Sokoto was restricted to infants of HIV-positive mothers who had ANC and participated in PMTCT program in the facility. Also, the proportion of HIV-positive mothers who never received HAART during pregnancy (8.9%) in the present study is higher than 7% reported by Onankpa and Tahir. [10] HIV positivity rate among infants of HIV-positive mothers was higher (28.6%) in babies whose mothers did not receive HAART during pregnancy compared to those whose mothers commenced during pregnancy (5.4%) and it was lowest (3.4%) in those whose mothers commenced HAART before pregnancy and the difference was statistically significant (p =0.01). This finding is consistent with findings from previous studies.[10,15] Positive HIV reactivity rate in exposed infants seen in EkSUTH is high and is a call for intensified effort to reaching out to women of child-bearing age and ensuring all pregnant women are screened for HIV early and commenced on HAART if need be. Also, all babies should be routinely screened for HIV at birth as a way of identifying mothers who may have been missed during pregnancy and also for early enrolment of exposed babies for EID. Majority (89.9%) of the infants in the present study were exclusively breastfed, and this is consistent with findings in the Northern part of Nigeria[10] and Zambia[15] where proportion of HIV exposed-infants who were exclusively breastfed was reported as 85.3% and 84.0% respectively. Although nine of the infants who tested positive to HIV were exclusively breastfed, this study showed that breastfeeding did not increase the likelihood of an infant testing positive to HIV. It is however noteworthy that 1.9% of our studied exposed infants had mixed feeding and all of them tested negative to HIV. This is surprising as other researchers have highlighted the high risk of mother to child transmission in the mixed feeding method.[6,10,16] It could be explained by the fact that we had a mixed population of babies delivered within and outside EkSUTH whose mothers probably didn`t receive proper counseling on feeding options prior to their delivery as some were actually referred to the centre after the delivery even though continuous counseling on feeding methods were integral parts of the care package given to the mothers during the treatment. There is therefore the need to extend teaching on EID and feeding of HIV-exposed babies beyond the walls of teaching hospitals to other places where deliveries take place; since 60% of all deliveries takes place where there are no skilled care.[17,18] It must however, be stated clearly that only exclusive breastfeeding and/or feeding with breast milk substitute alone has been shown to be safer than mixed feeding as a feeding option for infants of HIV positive mothers.[9] Early mixed feeding has been associated with four-fold risk of HIV transmission at six months of age for HIV-exposed babies who previously tested negative at six weeks of age.[6,10,16] The proportion of discordant couples in the present study was 39.9% while the HIV status of majority (57.6%) of the fathers was unknown. This may be a pointer to lack of family support for HIV-positive mothers and their exposed babies, which may encourage mixed feeding and none- compliance with treatment in a bid to hide their HIV status from their husbands and relatives, thereby increasing the risk of infection in the exposed babies. There seems to be no comparative advantage regarding whether the exposed infants were delivered per vaginal or through Caesarean section. This is reassuring for mothers and families with HIV positivity who might have been made to believe that operative delivery better protects against the risk of MTCT of HIV.[19-21] Though our findings report the results from one center and further expansion may be needed to ascertain the generalizability of these observations, it is nevertheless reassuring for the people living in third world countries for whom such delivery method may be too costly to bear in terms of the financial implications and the attendant huge morbidity and even mortality that could follow the method of delivery. Therefore, our findings underscore the fact that, given appropriate timely treatments, mothers with HIV infection need not be subjected to needless Caesarean sections, if not clinically indicated. Also, universal precaution and safety should be maintained during any invasive surgical procedure. Administration of Nevirapine for the first 6 weeks of life to HIV-exposed infants significantly contributed to prevention of infection in the present study: few (2.7%) of those who received Nevirapine in the first 6 weeks of life had positive PCR results compared to 54.5% of those who did not and the difference was statistically significant (p = 0.001). There is need to encourage the government and global health donors funding organizations and partners to ensure availability of this drug for all exposed babies so as to ensure the effectiveness of the PMTCT program. Prior studies have reported the importance of global health donor funding in the reduction of HIV prevalence in developing countries.[22,23] Moreover, in view of global economic recession with greater impact on developing countries, where more people are living with HIV,[1,9] global health donors should sustain their efforts in assisting developing countries combat the HIV pandemic.

Conclusions and Global Health Implications

Positive reaction to PCR in HIV-exposed infants seen at EkSUTH is relatively high; however commencement of HAART in HIV-positive mothers before pregnancy and administration of Nevirapine to exposed babies for the first 6 weeks of life significantly reduced transmission of HIV from mothers to children. There is need for more sustained efforts at optimizing early infant diagnosis at ART centers in low and middle-income countries through increased supports from governments and other stakeholders. The effectiveness of PMTCT program can be greatly enhanced by extending early infant diagnosis and treatment to all babies delivered in health facilities outside teaching hospitals. There is an ongoing need for continued and sustained funding of HIV prevention and treatment programs in developing countries such as Nigeria.
  13 in total

1.  ACOG committee opinion scheduled Cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234, May 2000 (replaces number 219, August 1999).

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  2001-06       Impact factor: 3.561

2.  Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection.

Authors:  John S Lambert; D Robert Harris; E Richard Stiehm; John Moye; Mary Glenn Fowler; William A Meyer; James Bethel; Lynne M Mofenson
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-15       Impact factor: 3.731

3.  Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group.

Authors:  C Kind; C Rudin; C A Siegrist; C A Wyler; K Biedermann; U Lauper; O Irion; J Schüpbach; D Nadal
Journal:  AIDS       Date:  1998-01-22       Impact factor: 4.177

4.  Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.

Authors:  Jeffrey Sa Stringer; Moses Sinkala; Courtney C Maclean; Jens Levy; Chipepo Kankasa; Alain Degroot; Elizabeth M Stringer; Edward P Acosta; Robert L Goldenberg; Sten H Vermund
Journal:  AIDS       Date:  2005-08-12       Impact factor: 4.177

5.  Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival.

Authors:  Peter J Iliff; Ellen G Piwoz; Naume V Tavengwa; Clare D Zunguza; Edmore T Marinda; Kusum J Nathoo; Lawrence H Moulton; Brian J Ward; Jean H Humphrey
Journal:  AIDS       Date:  2005-04-29       Impact factor: 4.177

6.  4 million neonatal deaths: when? Where? Why?

Authors:  Joy E Lawn; Simon Cousens; Jelka Zupan
Journal:  Lancet       Date:  2005 Mar 5-11       Impact factor: 79.321

7.  Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification.

Authors:  David S Boyle; Dara A Lehman; Lorraine Lillis; Dylan Peterson; Mitra Singhal; Niall Armes; Mathew Parker; Olaf Piepenburg; Julie Overbaugh
Journal:  MBio       Date:  2013-04-02       Impact factor: 7.867

8.  Dynamics and constraints of early infant diagnosis of HIV infection in Rural Kenya.

Authors:  Amin S Hassan; Erick M Sakwa; Helen M Nabwera; Miriam M Taegtmeyer; Robert M Kimutai; Eduard J Sanders; Ken K Awuondo; Maureen N Mutinda; Catherine S Molyneux; James A Berkley
Journal:  AIDS Behav       Date:  2012-01

9.  Reducing mother-to-child transmission of HIV: findings from an early infant diagnosis program in south-south region of Nigeria.

Authors:  Chukwuemeka Anoje; Bolatito Aiyenigba; Chiho Suzuki; Titilope Badru; Kesiena Akpoigbe; Michael Odo; Solomon Odafe; Oluwasanmi Adedokun; Kwasi Torpey; Otto N Chabikuli
Journal:  BMC Public Health       Date:  2012-03-12       Impact factor: 3.295

10.  Analysis of HIV early infant diagnosis data to estimate rates of perinatal HIV transmission in Zambia.

Authors:  Kwasi Torpey; Justin Mandala; Prisca Kasonde; Gail Bryan-Mofya; Maximillian Bweupe; Jonathan Mukundu; Chilunje Zimba; Catherine Mwale; Hilary Lumano; Michael Welsh
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more
  5 in total

1.  HIV-free survival among breastfed infants born to HIV-positive women in northern Uganda: a facility-based retrospective study.

Authors:  Irene Aguti; Charles Kimbugwe; Patricia Apai; Siraji Munyaga; Richard Nyeko
Journal:  Pan Afr Med J       Date:  2020-12-02

2.  Final HIV status outcome for HIV-exposed infants at 18 months of age in nine states and the Federal Capital Territory, Nigeria.

Authors:  Babatunde Adelekan; Bidemi Harry-Erin; Martha Okposo; Ahmad Aliyu; Nicaise Ndembi; Patrick Dakum; Nadia A Sam-Agudu
Journal:  PLoS One       Date:  2022-02-14       Impact factor: 3.240

3.  A Review and Analysis of Outcomes from Prevention of Mother-to-Child Transmission of HIV Infant Follow-up Services at a Pediatric Infectious Diseases Unit of a Major Tertiary Hospital in Nigeria: 2007-2020.

Authors:  Ebelechuku F Ugochukwu; Chinyere U Onubogu; Emeka S Edokwe; Uchenna Ekwochi; Kenneth N Okeke; Esther N Umeadi; Stanley K Onah
Journal:  Int J MCH AIDS       Date:  2021-12-15

Review 4.  Mother-to-child transmission of human immunodeficiency virus, hepatitis B virus and hepatitis C virus among pregnant women with single, dual or triplex infections of human immunodeficiency virus, hepatitis B virus and hepatitis C virus in Nigeria: A systematic review and meta-analysis.

Authors:  George Uchenna Eleje; Chinyere Ukamaka Onubogu; Preye Owen Fiebai; Ikechukwu Innocent Mbachu; Godwin Otuodichinma Akaba; Olabisi Morebise Loto; Hadiza Abdullahi Usman; Ayyuba Rabiu; Moriam Taiwo Chibuzor; Rebecca Chinyelu Chukwuanukwu; Ngozi Nneka Joe-Ikechebelu; Chike Henry Nwankwo; Stephen Okoroafor Kalu; Chukwuanugo Nkemakonam Ogbuagu; Shirley Nneka Chukwurah; Chinwe Elizabeth Uzochukwu; Ijeoma Chioma Oppah; Aishat Ahmed; Richard Obinwanne Egeonu; Chiamaka Henrietta Jibuaku; Samuel Oluwagbenga Inuyomi; Bukola Abimbola Adesoji; Ubong Inyang Anyang; Uchenna Chukwunonso Ogwaluonye; Ekene Agatha Emeka; Odion Emmanuel Igue; Ogbonna Dennis Okoro; Prince Ogbonnia Aja; Chiamaka Perpetua Chidozie; Hadiza Sani Ibrahim; Fatima Ele Aliyu; Aisha Ismaila Numan; Solace Amechi Omoruyi; Osita Samuel Umeononihu; Chukwuemeka Chukwubuikem Okoro; Ifeanyi Kingsley Nwaeju; Arinze Anthony Onwuegbuna; Eric Okechukwu Umeh; Sussan Ifeyinwa Nweje; Lydia Ijeoma Eleje; Ifeoma Clara Ajuba; David Chibuike Ikwuka; Emeka Philip Igbodike; Chisom God'swill Chigbo; Uzoamaka Rufina Ebubedike; Chigozie Geoffrey Okafor; Nnaedozie Paul Obiegbu; Ibrahim Adamu Yakasai; Oliver Chukwujekwu Ezechi; Joseph Ifeanyichukwu Ikechebelu
Journal:  SAGE Open Med       Date:  2022-04-28

5.  Prevention of Mother-to-Child Transmission and Early Real-Time DNA Polymerase Chain Reaction Results Among HIV-Exposed Infants in Bujumbura, Burundi.

Authors:  Joseph Nyandwi; Sylvestre Bazikamwe; Désiré Nisubire; Pontien Ndabashinze; Mohamed Elsayed Shaker; Eman Said
Journal:  East Afr Health Res J       Date:  2018-11-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.